Full Title
Optimizing Frontline Therapy for Diffuse Large B cell Lymphoma (DLBCL) in Older Adults: A GLOfitamab-Based, Response-Adapted, Window-StYle Study (GLORY)Purpose
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
If you join this study, you will get glofitamab, polatuzumab, and obinutuzumab plus standard chemotherapy. The standard treatment includes rituximab, cyclophosphamide, doxorubicin, and prednisone.
You will also have an imaging technique called positron emission tomography/computed tomography (PET/CT) scanning. Doctors will use it to see how many cycles of chemotherapy you need. Using PET-CT scanning may enable your doctors to reduce the amount of chemotherapy needed to treat your lymphoma.
Who Can Join
To join this study, there are a few conditions. You must:
- Have DLBCL, HGBCL, or transformed lymphoma that has not yet been treated.
- Be age 65 or older.
Contact
For more information or to see if you can join this study, please call Dr. Pallawi Torka’s office at 201-775-7808.